Posts Tagged ‘linagliptin’

October 28th, 2013

Selections from Richard Lehman’s Literature Review: October 28th

This week’s topics include thrombus aspiration during STEMI, the effect of statins on mortality in patients with ventilator-associated pneumonia, and more.

August 21st, 2012

Shining a Light on Standards at Medical Journals

, and

Recent articles in the diabetes literature might provide more evidence about editorial standards than about glycemic control.

August 8th, 2012

Selections from Richard Lehman’s Literature Review: August 8th

This week’s topics include heart failure and depression, endoscopic vs. open vein-graft harvest for CABG, linagliptin vs. glimepiride in those with type-2 diabetes, weight gain with smoking cessation, ACE inhibitors and pneumonia risk, and the effect of speech therapy after stroke.

June 29th, 2012

Linagliptin and Glimepiride Compared in Type 2 Diabetes

Sulfonylureas are often added to metformin to improve glycemic control, but at the known risk of increasing hypoglycemia and weight gain. In a report published in the Lancet, more than 1,500 patients with type 2 diabetes taking metformin were randomized to the addition of either linagliptin, a dipeptidyl peptidase-4 inhibitor, or glimepiride, a sulfonylurea. After two years, the trial […]

May 2nd, 2011

FDA Approves New Drug for Type 2 Diabetes

The FDA announced today that it has approved linagliptin, a new drug for type 2 diabetes. The DPP-4 inhibitor was developed by Eli Lilly and Boehringer Ingelheim and will be sold under the brand name of Tradjenta. Linagliptin was studied in 3,800 patients with type 2 diabetes, the FDA said, and was better than placebo in […]